NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Protection Against Severe Coronavirus Disease 2019 in Patients With Multiple Sclerosis Stratified According to Disease Modifying Treatment

NCT05834335

CompletedN/A

Sponsor: National MS Center Melsbroek

Conditions: Multiple Sclerosis

Countries: Belgium

The investigators will conduct retrospective observational cohort study at the Nationaal Multiple Sclerose Centrum (NMSC) Melsbroek (Belgium), which is a large center specifically focusing on neurological management, multidisciplinary care and/or rehabilitation in patients with MS. Primary endpoint For each DMT category, as defined above, the proportion of patients with a worse COVID-19 outcome (i.e., hospitalization and/or death) will be compared between those 'protected' versus 'unprotected' by vaccination at the time of SARS-CoV-2 infection. Corrections will be applied for any eventual imbalance in demographics, potentially relevant to COVID-19 outcome, between subgroups that are compared to each other, if indicated/feasible.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* diagnosis of multiple sclerosis
* positive selftest or PCR test Coronavirus

Exclusion Criteria:

* none

Locations (1)

Melsbroek, Vlaams Brabant, Belgium